Two -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naive or Relapsed/Refractory Waldenstrom's Macroglobulinemiatwo -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naive or Relapsed/Refractory Waldenstrom's Macroglobulinemia

被引：2
|
作者：
Suzuki, Kenshi
Sekiguchi, Naohiro
Rai, Shinya
Munakata, Wataru
Handa, Hiroshi
Shibayama, Hirohiko
Endo, Tomoyuki
Terui, Yasuhito
Iwaki, Noriko
Fukuhara, Noriko
Kelida, Shinsu
Ishikawa, Takayuki
Iguchi, Daisuke
Izutsu, Koji
机构：
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-146744
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1352
引用
收藏
页数：5
相关论文
共 39 条
  • [1] Phase 2 Study of Tirabrutinib (ONO/GS-4059), a Second-Generation Bruton's Tyrosine Kinase Inhibitor, Monotherapy in Patients with Treatment-Naive or Relapsed/Refractory Waldenstrom Macroglobulinemia
    Munakata, Wataru
    Sekiguchi, Naohiro
    Shinya, Rai
    Suzuki, Kenshi
    Handa, Hiroshi
    Shibayama, Hirohiko
    Endo, Tomoyuki
    Terui, Yasuhito
    Iwaki, Noriko
    Fukuhara, Noriko
    Tatetsu, Hiro
    Iida, Shinsuke
    Ishikawa, Takayuki
    Shiibashi, Ryota
    Izutsu, Koji
    BLOOD, 2019, 134
  • [2] Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma
    Narita, Yoshitaka
    Nagane, Motoo
    Mishima, Kazuhiko
    Terui, Yasuhito
    Arakawa, Yoshiki
    Yonezawa, Hajime
    Asai, Katsunori
    Fukuhara, Noriko
    Sugiyama, Kazuhiko
    Shinojima, Naoki
    Kitagawa, Junsaku
    Aoi, Arata
    Nishikawa, Ryo
    NEURO-ONCOLOGY, 2021, 23 (01) : 122 - 133
  • [3] A Prospective Multicenter Study Of The Bruton's Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom's Macroglobulinemia
    Treon, Steven Peter
    Tripsas, Christina K.
    Yang, Guang
    Cao, Yang
    Xu, Lian
    Hunter, Zachary
    Cropper, Steven J.
    Mostyn, Patrick
    Meid, Kirsten
    Warren, Diane
    Patterson, Christopher
    Varma, Gaurav
    Laubach, Jacob P.
    Paba-Prada, Claudia E.
    Kunsman, Janet
    Ghobrial, Irene M.
    Kanan, Sandra
    Advani, Ranjana H.
    Palomba, Maria Lia
    BLOOD, 2013, 122 (21)
  • [4] Extended follow-up with the Bruton's tyrosine kinase inhibitor ibrutinib in previously treated Waldenstrom's macroglobulinemia
    Furman, Richard R.
    Luan, Ying
    Bilotti, Elizabeth
    Graef, Thorsten
    LEUKEMIA & LYMPHOMA, 2017, 58 (06) : 1502 - 1505
  • [5] A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenstrom Macroglobulinemia
    An, Gang
    Zhou, Daobin
    Cheng, Shu
    Zhou, Keshu
    Li, Jianyong
    Zhou, Jianfeng
    Xie, Liping
    Jin, Jie
    Zhong, Liye
    Yan, Lingzhi
    Guo, Haiyi
    Du, Chenmu
    Zhong, Jinhua
    Yu, Yiling
    Wu, Binghao
    Qiu, Lugui
    CLINICAL CANCER RESEARCH, 2021, 27 (20) : 5492 - 5501
  • [6] THE BRUTON'S TYROSINE KINASE INHIBITOR IBRUTINIB IS HIGHLY ACTIVE AND TOLERABLE IN RELAPSED OR REFRACTORY (R/R) AND TREATMENT NAIVE (TN) CLL PATIENTS, UPDATED RESULTS OF A PHASE IB/II STUDY
    O'Brien, S.
    Furman, R.
    Coutre, S.
    Burger, J.
    Blum, K.
    Sharman, J.
    Flinn, I.
    Grant, B.
    Heerema, N.
    Johnson, A.
    Navarro, T.
    James, D.
    Hedrick, E.
    Byrd, J.
    HAEMATOLOGICA, 2012, 97 : 218 - 218
  • [7] ONE-YEAR FOLLOW-UP DATA OF PHASE I/II STUDY OF TIRABRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
    Mishima, Kazuhiko
    Narita, Yoshitaka
    Nagane, Motoo
    Terui, Yasuhito
    Arakawa, Yoshiki
    Yonezawa, Hajime
    Asai, Katsunori
    Fukuhara, Noriko
    Sugiyama, Kazuhiko
    Shinojima, Naoki
    Aoi, Arata
    Nishikawa, Ryo
    NEURO-ONCOLOGY, 2020, 22 : 57 - 58
  • [8] Phase 1/2 Study of Tirabrutinib (ONO/GS-4059), a Next-Generation Bruton's Tyrosine Kinase (BTK) Inhibitor, Monotherapy in Patients with Relapsed/ Refractory Primary Central Nervous System Lymphoma (PCNSL)
    Nagane, Motoo
    Narita, Yoshitaka
    Mishima, Kazuhiko
    Terui, Yasuhito
    Arakawa, Yoshiki
    Yonezawa, Hajime
    Asai, Katsunori
    Fukuhara, Noriko
    Sugiyama, Kazuhiko
    Shinojima, Naoki
    Kitagawa, Junsaku
    Aoi, Arata
    Nishikawa, Ryo
    BLOOD, 2019, 134
  • [9] Final three-year follow-up analysis of phase I/II study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma
    Asai, Katsunori
    Narita, Yoshitaka
    Nagane, Motoo
    Mishima, Kazuhiko
    Terui, Yasuhito
    Arakawa, Yoshiki
    Yonezawa, Hajime
    Fukuhara, Noriko
    Sugiyama, Kazuhiko
    Shinojima, Naoki
    Aoi, Arata
    Nishikawa, Ryo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059)
    Rule, Simon A.
    Cartron, Guillaume
    Fegan, Christopher
    Morschhauser, Franck
    Han, Lingling
    Mitra, Siddhartha
    Salles, Gilles
    Dyer, Martin J. S.
    LEUKEMIA, 2020, 34 (05) : 1458 - 1461
1234